MENU
+Compare
BIOA
Stock ticker: NASDAQ
AS OF
Jan 14, 04:59 PM (EDT)
Price
$22.93
Change
+$2.24 (+10.83%)
Capitalization
821.8M

BIOA stock forecast, quote, news & analysis

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging... Show more

BIOA
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for BIOA with price predictions
Jan 13, 2026

BIOA in -9.67% downward trend, declining for three consecutive days on January 08, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BIOA declined for three days, in of 61 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

BIOA broke above its upper Bollinger Band on January 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 12, 2026. You may want to consider a long position or call options on BIOA as a result. In of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BIOA just turned positive on January 12, 2026. Looking at past instances where BIOA's MACD turned positive, the stock continued to rise in of 10 cases over the following month. The odds of a continued upward trend are .

Following a +4 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOA advanced for three days, in of 81 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 41 cases where BIOA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BIOA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.962) is normal, around the industry mean (29.656). P/E Ratio (1.684) is within average values for comparable stocks, (75.571). BIOA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.019). BIOA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (138.889) is also within normal values, averaging (72.365).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.57B. The market cap for tickers in the group ranges from 2.12K to 65.17B. MKKGY holds the highest valuation in this group at 65.17B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -0%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was 20%. MILFF experienced the highest price growth at 37%, while SXTC experienced the biggest fall at -94%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 28%. For the same stocks of the Industry, the average monthly volume growth was -71% and the average quarterly volume growth was -1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 56
SMR Rating: 80
Profit Risk Rating: 89
Seasonality Score: 23 (-100 ... +100)
View a ticker or compare two or three
BIOA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a producer of sustainable chemicals

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Chemicals Specialty
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A